Cancer Screening in Los Angeles & Orange County

What if you found cancer early enough to make a difference?

Through a simple blood draw the Galleri™ test looks at DNA in your blood to determine if any of it may have com from cancer cells. A multi-cancer early detection test can detect many cancers to improve the chance of finding cancer early. It is time to look at cancer more broadly, in addition to the 5 cancers that are routinely screened. A multi-cancer early detection test can detect many cancers to improve the chance of finding cancer early.

Who can benefit?

The Galleri test is recommended for use in adults with an elevated risk of cancer, such as those aged 50 or older. The Galleri test is intended to be used in addition to, and not to replace, other cancer screening tests your healthcare provider recommends.

Schedule an Appointment

71% of cancer deaths are caused by cancers not commonly screened for.

Videos

Introducing the Galleri test

The Galleri Multi-Cancer Early Detection Test detects more than 50 types of cancer through a simple blood draw. Offering the benefits of:

Hourglass Icon

Early cancer detection

Detects many cancers that are not commonly screened for today, to allow for earlier treatment.

Stethescope Icon

Testing with ease

Can be easily incorporated into a routine healthcare visit.

Chart Icon

Actionable results

If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help your healthcare provider guide your next steps.

Frequently Asked Questions

What is the importance of early detection?

  • Finding cancer early is important to improve treatment outcomes and survival.1
  • The vast majority of cancers show no symptoms until later stages, when treatment options may be limited.2
  • Today, there are 5 recommended cancer screening tests that together only account for 1 in 4 diagnosed cancers in patients over 50 years of age.3,4
  • 71% of cancer deaths are caused by cancers not commonly screened for today.5, 6
  • When cancers are diagnosed early before they have had a chance to spread, the overall 5-year survival rate is 4x higher than when diagnosed in later stages.1, 7
  • The most important cancer is the one that you or your loved one may have – and beating it starts with knowing you have it.

 

What is Multi-Cancer Early Detection?

  • Multi-cancer early detection enables you to proactively screen for many cancers at once, increasing the chances of finding cancer early.

 

What is the Galleri test and what are the benefits?

  • The Galleri test detects more than 50 types of cancer through a simple blood draw.8, 9
  • Test benefits:
  1. Early cancer detection
    1. Early detection can help improve treatment outcomes and survival. The Galleri test detects many cancers that are not commonly screened for today, to allow for earlier treatment.9, 10
  2. Testing with ease
    1. The Galleri test can be incorporated into a routine healthcare visit through a simple blood draw.
  3. Actionable results
    1. If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help guide your next steps.

 

Who can benefit from the Galleri test?

  • The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is intended to be used in addition to and not replace other cancer screening tests your healthcare provider recommends.
  • People aged 50 and above have a 13x increased risk for cancer.11

 

How does the Galleri test work?

  • All cells in your body release DNA into the bloodstream, but DNA from cancer cells is different from the DNA of healthy cells.12 The Galleri test looks at the DNA in your blood to determine if any of it may have come from cancer cells, and the results can point to where in the body the cancer is coming from.

 

Where can I learn more?


REFERENCES
1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data, Nov
2018 Submission. Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ
of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
2. Cancer Facts and Figures 2021 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf
3. Modeled detection extrapolated to 2020 US population ages 50–79
4. Calculated by internal analysis using data from SEER*Stat Database: Incidence which represents 34.6% of US population – SEER 18 Regs Research Data,
Nov 2018 Submission. Includes persons aged 50–79 diagnosed 2006-2015. Pinsky. J Med Screen.
2012;19(3):154-156: 33% of lung cancers in US among National Lung Screening Trial eligible population. Screening includes methods with United States
Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung). 5. Modeled detection extrapolated to 2020 US population ages 50–79. Screening includes methods with United States Preventive Services Task Force
(USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung), and assumes screening is available for all prostate, breast, cervical, and colorectal
cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
6. Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50–79.
Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer-org/
research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
7. Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/
csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.
8. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)
9. Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
10. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to guideline-recommended cancer screenings such as mammography, colonoscopy, PSA, or cervical cancer screening.
11. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017):
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/eancer/da
taviz, released in June 2020.
12. Bronkhorst AJ, et al. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. https://www.sciencedirect.com/science/article/pii/S221475351830024X